A recent article has demonstrated the validity of a new top-down proteomics approach to identifying low-abundance biomarkers in the one per cent of serum/plasma proteins known as the deep proteome. The study used a 4-step approach including sample collection, fractionation with proteominer technology, biomarker discovery with SELDI and biomarker identification using the Lucid system to identify a potential biomarker that might be used to track a patient’s recovery from a myocardial infarction (heart attack).
According to Bio-Rad product manager Dominic Casenas, ‘The workflow in this publication provides scientists with a promising approach for accessing, profiling, and identifying clinically relevant biomarkers.’
Read more on the laboratory talk website.
Check out the video below for an entertaining look at how combining top-down and bottom-up proteomics will change biomarker research forever.